In my view the future of Neuren depends on whether the board wants it to continue as a standalone entity or not. If they are angling for an exit strategy then they will keep everything simplified. ie no licensing deals to external pharma companies for 2591. Instead they will pursue non dilutive capital to fund the phase 3's. This makes Neu a more enticing takeover target with less to negotiate. I think something we have to consider in this instance will be a merger with Acadia who cant afford to buy us outright but could do a cash and script deal. They both operate in the same space and there will be obvious savings and synergy....
if the board want to keep their jobs and Neuren continues alone then the more complicated the deals to fund phase 3's the better!!
- Forums
- ASX - By Stock
- Share Price
In my view the future of Neuren depends on whether the board...
-
- There are more pages in this discussion • 2,535 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add NEU (ASX) to my watchlist
(20min delay)
|
|||||
Last
$15.27 |
Change
0.920(6.41%) |
Mkt cap ! $1.951B |
Open | High | Low | Value | Volume |
$14.35 | $15.27 | $14.35 | $8.720M | 579.3K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 1000 | $15.25 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$15.27 | 3638 | 4 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 650 | 15.200 |
2 | 1100 | 15.000 |
1 | 36 | 14.860 |
1 | 100 | 14.850 |
1 | 500 | 14.830 |
Price($) | Vol. | No. |
---|---|---|
15.300 | 1425 | 1 |
15.500 | 2020 | 2 |
15.700 | 100 | 1 |
15.800 | 50 | 1 |
15.900 | 1334 | 2 |
Last trade - 16.10pm 27/09/2024 (20 minute delay) ? |
Featured News
NEU (ASX) Chart |